Abstracts tagged "Sjogren’s syndrome"

Abstract Number: 2682 • 2016 ACR/ARHP Annual Meeting
How Does Primary Sjogren Syndrome Present in Biopsy-Proven Patients without Circulating Ro/La Autoantibodies? Characteristics at Diagnosis of 2073 Patients from the SjöGren Big Data Project
Pilar Brito-Zerón^1,2,3, Nihan Acar-Denizli⁴, Margit Zeher⁵, Astrid Rasmussen⁶, Raphaele Seror⁷, Elke Theander⁸, Xiaomei Li⁹, Chiara Baldini¹⁰, Jacques-Eric Gottenberg¹¹, Debashish Danda¹², Luca Quartuccio¹³, Roberta Priori^14,15, Gabriela Hernandez-Molina¹⁶, Aike A. Kruize¹⁷, Valeria Valim¹⁸, Marika Kvarnström¹⁹, Damien Sene²⁰, Roberto Gerli²¹, Sonja Praprotnik²², David A. Isenberg²³, Roser Solans²⁴, Maureen Rischmueller²⁵, Seung-Ki Kwok²⁶, Gunnel Nordmark²⁷, Yasunori Suzuki²⁸, Roberto Giacomelli²⁹, Valerie Devauchelle-Pensec³⁰, Michele Bombardieri³¹, Benedikt Hofauer³², Hendrika Bootsma³³, Johan G. Brun³⁴, Guadalupe Fraile³⁵, Steven E. Carsons³⁶, Tamer Gheita³⁷, Jacques Morel³⁸, Cristina F. Vollenweider³⁹, Fabiola Atzeni⁴⁰, Soledad Retamozo⁴¹, Ildike-Fanny Horvath⁵, Kathy Sivils⁶, Thomas Mandl^42,43, Pulukool Sandhya¹², Salvatore De Vita⁴⁴, Jorge Sánchez-Guerrero⁴⁵, Eefje van der Heijden¹⁷, Virginia Moça Trevisano⁴⁶, Marie Wahren-Herlenius¹⁹, Xavier Mariette⁷, Manuel Ramos-Casals^3,47,48 and EULAR-SS Task Force Big Data Consortium (ASSES, GEAS-SEMI, EULAR), ¹Autoimmune Diseases Unit, Department of Medicine, Hospital CIMA- Sanitas, Barcelona., Bacelona, Spain, ²Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Barcelona, Spain, ³Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ⁴Department of Statistics, Faculty of Science and Letters, Mimar Sinan Fine Arts University, Turkey, Istabul, Turkey, ⁵Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary., Debrecen, Hungary, ⁶Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, USA, Oklahoma City, OK, ⁷Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, Paris, France, ⁸Department of Rheumatology, Malmö University Hospital, Lund University, Sweden, Malmö, Sweden, ⁹Department of Rheumatology and Immunology, Anhui Medical University Affiliated Provincial Hospital, China, Hefei, Anhui, China, ¹⁰Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ¹¹Department of Rheumatology, Strasbourg University Hospital, Université de Strasbourg, CNRS, Strasbourg, France, Strasbourg, France, ¹²Clinical Immunology & Rheumatology, Christian Medical College, Vellore, India, Vellore, India, ¹³Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, Udine, Italy, ¹⁴Rheumatology Unit, Sapienza University of Rome, Rome, Italy, ¹⁵Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ¹⁶Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico City, Mexico, ¹⁷Department of Rheumatology & Clinical Immunology, Medical Center Utrecht, The Netherlands, Utrecht, Netherlands, ¹⁸Rheumatology, Department of Medicine, Universidade Federal do Espírito Santo, Vitória, Brazil, Vitória, Brazil, ¹⁹Department of Medicine, Solna, Unit of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ²⁰Service de Médecine Interne 2, Hôpital Lariboisière, Université Paris VII, Assistance Publique-Hôpitaux de Paris, 2, Paris, France, Paris, France, ²¹Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Italy, Perugia, Italy, ²²Department of Rheumatology, University Medical Centre Ljubljana, Slovenia, Ljubljana, Slovenia, ²³Centre for Rheumatology Research, University College Hospital London, UK, London, United Kingdom, ²⁴Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Spain, Barcelona, Spain, ²⁵Department of Rheumatology, School of Medicine, The University of Western Australia, Crawley, Australia, Crawley, Australia, ²⁶[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ²⁷Rheumatology, Department of Medical Sciences, Uppsala University, Sweden, Uppsala, Sweden, ²⁸Division of Rheumatology , Kanazawa University Hospital , Kanazawa , Ishikawa , Japan, Ishikawa, Japan, ²⁹Clinical Unit of Rheumatology, University of l'Aquila, School of Medicine, L'Aquila, Italy, L'Aquila, Italy, ³⁰Department of Rheumatology, Brest University Hospital, Brest, France, Brest, France, ³¹Willian Harvey Research Institute, Centre for Experimental Medicine and Rheumatology, QMUL, UK, London, United Kingdom, ³²Hals-Nasen-Ohrenklinik und Poliklinik, Technische Universität München, München, Germany, München, Germany, ³³Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, The Netherlands, Groningen, Netherlands, ³⁴Department of Clinical Science, University of Bergen. Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, Bergen, Norway, ³⁵Department of Internal Medicine, Hospital Ramón y Cajal, Madrid, Spain, Madrid, Spain, ³⁶Division of Rheumatology, Allergy and Immunology Winthrop-University Hospital, Stony Brook University School of Medicine, NY, USA, Mineola, NY, ³⁷Rheumatology, Rheumatology Department, Faculty of Medicine, Cairo University, Egypt, Cairo, Egypt, ³⁸Department of Rheumatology, Teaching hospital and University of Montpellier, France, Montpellier, France, ³⁹Rheumatology, German Hospital, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁴⁰IRCCS Galeazzi Orthopedic Institute, Milan, Italy, Milan, Italy, ⁴¹Rheumatology Unit, Hospital Privado Centro Médico de Córdoba, Argentina, Córdoba, Argentina, ⁴²Department of Clinical Sciences Malmö, Lund University, Skåne University Hospital, Rheumatology, Malmö, Sweden, Malmö, Sweden, ⁴³Department of Rheumatology, Malmö University Hospital, Lund University, Sweden, Lund, Sweden, ⁴⁴Clinic of Rheumatology, Department of Medical and Biological Sciences, University Hospital "Santa Maria della Misericordia", Udine, Italy, Udine, Italy, ⁴⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico, ⁴⁶Federal University of São Paulo, Sao Paulo, Brazil, San Paulo, Brazil, ⁴⁷Sjögren Syndrome Research Group (AGAUR), Barcelona, Spain, ⁴⁸Department of Medicine, University of Barcelona, Barcelona, Spain., Barcelona, Spain
Background/Purpose: To analyse the main characteristics of patients with primary Sjögren syndrome (SjS) with focal lymphocytic sialadenitis (FLS) unrelated to the presence of circulating anti-Ro/La…
Abstract Number: 657 • 2016 ACR/ARHP Annual Meeting
Expression of Type-III Interferons (IFNλs) and Their Receptor in Sjögren’s Syndrome
Eirini Apostolou¹, Efstathia K. Kapsogeorgou², Orsia D. Konsta¹, Ioannis Giotakis³, Maria Ioanna Saridaki⁴, Evangelos Andreakos⁴ and Athanasios G. Tzioufas⁵, ¹Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ²Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ³2nd Otolaryngology, “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ⁴Immunology, Center for Clinical and Translational Research, Biomedical Research Foundation Academy of Athens, Athens, Greece, ⁵School of Medicine, Pathophysiology Department, National and Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Type-III IFNs or IFNλs(IFNλ1/IL29, IFNλ2/IL28A and IFNλ3/IL28B) consist a recently identified group of IFNs,initiallyimplicated inseveral human diseases, including cancer and autoimmunity. In this study,…
Abstract Number: 1401 • 2016 ACR/ARHP Annual Meeting
Ultrasonography of Major Salivary Glands in Juvenile SjöGren’s Syndrome − Preliminary Findings in a Multi-Center Study
Daniel S. Hammenfors¹, Valeria Valim², Vibke Lilleby³, Blanca Bica⁴, Sandra Gofinet Pasoto⁵, Clovis Silva⁶, Juan Carlos Nieto⁷, Scott Lieberman⁸, Akaluck Thatayatikom⁹, Roland Jonsson¹⁰, Johan G. Brun¹¹ and Malin V. Jonsson¹², ¹Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, ²Rheumatology, Department of Medicine, Universidade Federal do Espírito Santo, Vitória, Brazil, Vitória, Brazil, ³Rheumatology, Oslo University Hospital, Oslo, Norway, ⁴Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, Brazil, ⁵Internal Medicine, Division of Rheumatology - Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁶Department of Pediatric Rheumatology, Federal University of São Paulo, São Paulo, Brazil, ⁷Hospital General Universitario Gregorio Marañón and Complutense University, Madrid, Spain, ⁸Pediatrics (Division of Rheumatology), University of Iowa Children's Hospital, Iowa City, IA, ⁹University of Florida, Gainesville, FL, ¹⁰Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, ¹¹Department of Clinical Science, University of Bergen, Norway, Bergen, Norway, ¹²Department of Clinical Dentistry, Section for Oral and Maxillofacial Radiology, University of Bergen, Bergen, Norway
Background/Purpose: Juvenile Sjögren’s syndrome (jSS) is a rare, poorly defined and possibly underdiagnosed condition. Mean age of diagnosis is approximately 10 years, with major salivary…
Abstract Number: 2683 • 2016 ACR/ARHP Annual Meeting
Isolated Anti-La/SS-B Positivity in Patients Diagnosed with Primary Sjogren Syndrome: Analysis of 222 Patients from the Sjogren Big Data Cohort
Pilar Brito-Zerón^1,2,3, Nihan Acar-Denizli⁴, Margit Zeher⁵, Astrid Rasmussen⁶, Raphaele Seror⁷, Elke Theander⁸, Xiaomei Li⁹, Chiara Baldini¹⁰, Jacques-Eric Gottenberg¹¹, Debashish Danda¹², Luca Quartuccio¹³, Roberta Priori^14,15, Gabriela Hernandez-Molina¹⁶, Aike A. Kruize¹⁷, Valeria Valim¹⁸, Marika Kvarnström¹⁹, Damien Sene²⁰, Roberto Gerli²¹, Sonja Praprotnik²², David A. Isenberg²³, Roser Solans²⁴, Maureen Rischmueller²⁵, Seung-Ki Kwok²⁶, Gunnel Nordmark²⁷, Yasunori Suzuki²⁸, Roberto Giacomelli²⁹, Valerie Devauchelle-Pensec³⁰, Michele Bombardieri³¹, Benedikt Hofauer³², Hendrika Bootsma³³, Johan G. Brun³⁴, Guadalupe Fraile³⁵, Steven E. Carsons³⁶, Tamer Gheita³⁷, Jacques Morel³⁸, Cristina F. Vollenweider³⁹, Fabiola Atzeni⁴⁰, Soledad Retamozo⁴¹, Ildike-Fanny Horvath⁵, Kathy Sivils⁶, Thomas Mandl⁴², Pulukool Sandhya¹², Salvatore De Vita⁴³, Jorge Sánchez-Guerrero⁴⁴, Eefje van der Heijden¹⁷, Virginia Moça Trevisano⁴⁵, Marie Wahren-Herlenius¹⁹, Manuel Ramos-Casals^3,46,47 and EULAR-SS Task Force Big Bata Consortium (ASSES, GEAS-SEMI EULAR), ¹Autoimmune Diseases Unit, Department of Medicine, Hospital CIMA- Sanitas, Barcelona., Bacelona, Spain, ²Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Barcelona, Spain, ³Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ⁴Department of Statistics, Faculty of Science and Letters, Mimar Sinan Fine Arts University, Istambul, Turkey, ⁵Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary., Debrecen, Hungary, ⁶Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, USA, Oklahoma City, OK, ⁷Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, Paris, France, ⁸Department of Rheumatology, Malmö University Hospital, Lund University, Sweden, Malmö, Sweden, ⁹Department of Rheumatology and Immunology, Anhui Medical University Affiliated Provincial Hospital, China, Hefei, Anhui, China, ¹⁰University of Pisa, Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ¹¹Department of Rheumatology, Strasbourg University Hospital, Université de Strasbourg, CNRS, Strasbourg, France, Strasbourg, France, ¹²Clinical Immunology & Rheumatology, Christian Medical College, Vellore, India, Vellore, India, ¹³Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, Udine, Italy, ¹⁴Rheumatology Unit, Sapienza University of Rome, Rome, Italy, ¹⁵Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ¹⁶Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico City, Mexico, ¹⁷Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands, Utrecht, Netherlands, ¹⁸Department of Medicine, Universidade Federal do Espírito Santo, Vitória, Brazil, Vitória, Brazil, ¹⁹Department of Medicine, Solna, Unit of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ²⁰Service de Médecine Interne 2, Hôpital Lariboisière, Université Paris VII, Assistance Publique-Hôpitaux de Paris, 2, Paris, France, Paris, France, ²¹Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Italy, Perugia, Italy, ²²Department of Rheumatology, University Medical Centre Ljubljana, Slovenia, Ljubljana, Slovenia, ²³Centre for Rheumatology Research, University College Hospital London, UK, London, United Kingdom, ²⁴Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Spain, Barcelona, Spain, ²⁵Department of Rheumatology, School of Medicine, The University of Western Australia, Crawley, Australia, Crawley, Australia, ²⁶Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, South Korea, ²⁷Rheumatology, Department of Medical Sciences, Uppsala University, Sweden, Uppsala, Sweden, ²⁸Division of Rheumatology , Kanazawa University Hospital , Kanazawa , Ishikawa , Japan, Ishikawa, Japan, ²⁹Clinical Unit of Rheumatology, University of l'Aquila, School of Medicine, L'Aquila, Italy, L'Aquila, Italy, ³⁰Department of Rheumatology, Brest University Hospital, Brest, France, Brest, France, ³¹Willian Harvey Research Institute, Centre for Experimental Medicine and Rheumatology, QMUL, UK, London, United Kingdom, ³²Hals-Nasen-Ohrenklinik und Poliklinik, Technische Universität München, München, Germany, München, Germany, ³³Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, The Netherlands, Groningen, Netherlands, ³⁴Department of Clinical Science, University of Bergen. Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, Bergen, Norway, ³⁵Department of Internal Medicine, Hospital Ramón y Cajal, Madrid, Spain, Madrid, Spain, ³⁶Division of Rheumatology, Allergy and Immunology Winthrop-University Hospital, Stony Brook University School of Medicine, NY, USA, Mineola, NY, ³⁷Rheumatology, Rheumatology Department, Faculty of Medicine, Cairo University, Egypt, Cairo, Egypt, ³⁸Department of Rheumatology, Teaching hospital and University of Montpellier, France, Montpellier, France, ³⁹Rheumatology, German Hospital, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁴⁰IRCCS Galeazzi Orthopedic Institute, Milan, Italy, Milan, Italy, ⁴¹Rheumatology Unit, Hospital Privado Centro Médico de Córdoba, Argentina, Córdoba, Argentina, ⁴²Department of Rheumatology, Malmö University Hospital, Lund University, Sweden, Lund, Sweden, ⁴³Clinic of Rheumatology, Department of Medical and Biological Sciences, University Hospital "Santa Maria della Misericordia", Udine, Italy, Udine, Italy, ⁴⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico, ⁴⁵Federal University of São Paulo, Sao Paulo, Brazil, San Paulo, Brazil, ⁴⁶Sjögren Syndrome Research Group (AGAUR), Barcelona, Spain, ⁴⁷Department of Medicine, University of Barcelona, Barcelona, Spain., Barcelona, Spain
Background/Purpose: To describe the clinical, immunological and histopathological profile of patients with primary Sjögren syndrome (SjS) presenting with isolated circulating anti-La/SS-B antibodies in the absence…
Abstract Number: 659 • 2016 ACR/ARHP Annual Meeting
Low Dose IL-2 Therapy Can Restore the Balance of Th17 and Treg Cells in Refractory Patients with Sjogren’s Syndrome
Miao Miao¹, Shengxiao Zhang¹, Xiao-Qing Liu¹, Xiaoyan Wu², Chong Gao³ and Xiao-Feng Li², ¹The Second Hospital of Shanxi Medical University, Taiyuan, China, ²Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China, ³Department of Pathology, Joint Program in Transfusion Medicine, Brigham and Women’s Hospital/Children’s Hospital Boston, Harvard Medical School, Boston, MA, Cambridge, MA
Background/Purpose: The therapy for sjogren’s syndrome (SS) focuses on biological agents, immune inhibitors and glucocorticoid which can’t correct the problem of unbalance of Th17 and…
Abstract Number: 1516 • 2016 ACR/ARHP Annual Meeting
Evidence of Labial Salivary Gland Epithelial Cell Activation from Patients with Rheumatoid Arthritis and Sicca Symptomatology
George Fragoulis¹, James Reilly¹, Shauna Kerr¹, Iain B McInnes² and Haralampos M. Moutsopoulos³, ¹Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ²University of Glasgow, Glasgow, Great Britain, ³Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
Background/Purpose: In primary Sjögren’s syndrome (pSS), labial minor salivary gland epithelial cells (LMSGEC) inappropriately express various molecules, including B7, HLA-DR, ICAM, as assessed previously by…
Abstract Number: 2685 • 2016 ACR/ARHP Annual Meeting
Ultrasound of the Major Salivary Glands Is a Reliable Imaging Technique for Diagnosing Patients Clinically Suspected with SjöGren’s Syndrome
Konstantina Delli¹, Suzanne Arends², Pieter U. Dijkstra³, Jolien F. van Nimwegen², Alja J Stel², Hendrika Bootsma⁴, Arjan Vissink¹ and Fred K.L. Spijkervet⁵, ¹Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Department of Rehabilitation, Center for Rehabilitation, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁴Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, The Netherlands, Groningen, Netherlands, ⁵Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: In the classification criteria of Sjögren’s syndrome (SS), involvement of the salivary glands is currently assessed by sialography, scintigraphy, sialometry and histopathology. Recent discussions…
Abstract Number: 660 • 2016 ACR/ARHP Annual Meeting
Expression of the Chemokine Receptor CXCR5 Is Decreased in the Periphery of Patients with Primary Sjogren’s Syndrome
Marie Wahren-Herlenius¹, Lara Adnan Aqrawi¹, Margarita Ivanchenko¹, Albin Björk¹, Jorge Ramírez¹, Marika Kvarnström¹, Janicke Cecilie Liaaen Jensen² and Kathrine Skarstein³, ¹Karolinska Institutet, Stockholm, Sweden, ²University of Oslo, Oslo, Norway, ³University of Bergen, Bergen, Norway
Background/Purpose: CXCR5 is a chemokine receptor expressed on B and T cell subsets, which binds the CXCL13 ligand produced by follicular dendritic cells. It is…
Abstract Number: 1904 • 2016 ACR/ARHP Annual Meeting
Elevated GITRL Is Associated with Multi-Organ Involvement and Increased Disease Activity of Primarty Sjogren’s Syndrome and Promotes Pathogenic Th1/17 Differentiation
Xiaolin Sun¹, Yuzhou Gan Sr.², Jing He³ and Zhanguo Li⁴, ¹People's hospital,Peking University, Beijing, China, ²Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ³Peking Univerisity People's Hospital, Beijing, China, ⁴Peking University People's Hospital, Beijing, China
Background/Purpose: Accumulating data showed that Glucocorticoid-induced Tumor Necrosis Factor Receptor Family-related Protein (GITR), with its ligand (GITRL), plays an important role in promoting T-cell-mediated immunity…
Abstract Number: 2686 • 2016 ACR/ARHP Annual Meeting
Objective Improvement in Fatigue Scores for Primary Sjögren’s Patients Receiving a Tailored Multidisciplinary Fatigue Intervention in a Generic Fatigue Clinic
Katie Hackett^1,2, Robert Forder³, Dennis W Lendrem⁴, Ben Hargreaves⁵, Victoria Strassheim^1,3, Zoe Gotts³, Vincent Deary^1,6, Wan-Fai Ng^7,8 and Julia Newton^1,3, ¹CRESTA Fatigue Clinic, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ²Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ³Newcastle University, Newcastle upon Tyne, United Kingdom, ⁴Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁵Musculoskeletal Directorate, Newcastle upon Tyne NHS Foundation Trust, Newcastle, United Kingdom, ⁶School of Health Psychology, Northumbia University, Newcastle upon Tyne, United Kingdom, ⁷Musculoskeletal Research Group Institute of Cellular Medicine, Newcastle University, Newcastle University, Newcastle, England, ⁸Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
Background/Purpose: Primary Sjögren’s syndrome (PSS) is an autoimmune disease which targets secretary glands resulting in dry eyes and mouth. Approximately 70% of PSS patients experience…
Abstract Number: 11L • 2015 ACR/ARHP Annual Meeting
Preliminary Results of a Double-Blind Randomised Trial of Rituximab Anti-B-Cell Therapy in Patients with Primary Sjogrens Syndrome
Simon Bowman¹, Colin Everett², Michele Bombardieri³, Robert Busch⁴, Paul Emery⁵, Frances Hall⁶, Colin T. Pease⁷, Costantino Pitzalis⁸, Elizabeth Price⁹, Luke Dawson¹⁰, Peter Smith¹¹, Nurhan Sutcliffe³, Wan-Fai Ng¹², Catherine Fernandez¹³, Sharon Ruddock¹³, Linda Sharples¹³, Catherine Reynolds¹³ and Sue Pavitt¹⁴, ¹Rheumatology Dept, University Hospital Birmingham, Birmingham, United Kingdom, ²Leeds Institute for Clinical Trials Research, University of Leeds, LEEDS, United Kingdom, ³Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom, ⁴Department of Life Sciences, University of Roehampton, London, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds Gen Infirmary, Leeds, United Kingdom, ⁶School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom, ⁷Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁸Centre for Experimental Medicine & Rheumatology, Queen Mary's School of Medicine and Dentistry, London, United Kingdom, ⁹Rheumatology Department, Great Western Hospital, Swindon, United Kingdom, ¹⁰School of Dental Sciences, University of Liverpool,, Liverpool, United Kingdom, ¹¹School of Dental Sciences,, University of Liverpool, Liverpool, United Kingdom, ¹²NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle upon Tyne, United Kingdom, ¹³Leeds Institute for Clinical Trials Research, University of Leeds, Leeds, United Kingdom, ¹⁴Division of Applied Health & Clinical Translation , School of Dentistry, University of Leeds, Leeds, United Kingdom
Background/Purpose: Evidence from open-label and observational studies support anti-B-cell therapy in patients with primary Sjogren’s Syndrome (PSS). The TRACTISS trial aimed to determine the extent…
Abstract Number: 623 • 2015 ACR/ARHP Annual Meeting
Seronegative Sjögren’s Syndrome Is Characterized By a Lower Prevalence of B-Cell Related Clinical Manifestations and a Lower Biologic Systemic Activity
Luca Quartuccio¹, Chiara Baldini^2,3,4, Elena Bartoloni Bocci⁵, Roberta Priori⁶, Francesco Carubbi⁷, Laura Corazza¹, Alessia Alunno⁸, Serena Colafrancesco⁶, Nicoletta Luciano², Roberto Gerli⁹, Roberto Giacomelli¹⁰, Guido Valesini¹¹, Stefano Bombardieri¹² and Salvatore De Vita^13,14, ¹S. Maria della Misericordia, University of Udine, Italy, Udine, Italy, ²Internal Medicine, University of Pisa, Pisa, Italy, ³University of Pisa, Rheumatology Unit, Pisa, Italy, ⁴Department of Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁵Rheumatology Unit, Department of Medicine, University of Perugia, Pila, Italy, ⁶Rheumatology Unit, Sapienza University of Rome, Rome, Italy, ⁷Rheumatology Clinic, University of L'Aquila, L'Aquila, Italy, ⁸Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ⁹Rheumatology Clinic, University of Perugia, Perugia, Italy, ¹⁰University of L'Aquila, L'Aquila, Italy, ¹¹Internal Medicine and Medical Specialties Department, Policlinico Umberto I, La Sapienza University of Rome, Roma, Italy, ¹²Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ¹³Santa Maria della Misericordia Hospital, University of Udine, Udine, Italy, ¹⁴Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy
Background/Purpose: The American-European Consensus Group (AECG) Criteria (1) for Sjögren's syndrome (SS) require the presence of at least one of the following two conditions: the…
Abstract Number: 643 • 2015 ACR/ARHP Annual Meeting
Ethnicity of Sjögren’s Syndrome
Rohan Sharma¹, Astrid Rasmussen², Lida Radfar³, David M. Lewis⁴, Kiely Grundahl⁵, C. Erick Kaufman⁶, Donald U. Stone⁷, Joan T. Merrill⁸, Christopher Lessard⁹, Kathy L. Sivils⁹ and Robert Hal Scofield¹⁰, ¹Medical Service, US Department of Veterans Affaris Medical Center, Oklahoma City, OK, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oral Diagnosis and Radiology Department, University of Oklahoma Health Sciences Center College of Dentistry, Oklahoma City, OK, ⁴College of Dentistry, Department of Oral and Maxillofacial Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma CIty, OK, ⁶Medicine, University of Oklahoam Health Sciences Center, Oklahoma City, OK, ⁷Ophthalmology, University of Oklahoam Health Sciences Center; Dean McGee Eye Center, Oklahoma City, OK, ⁸Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁰Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: We undertook this study to describe the racial and ethnic diversity of SS compared to that found among patients with SLE. SLE is known…
Abstract Number: 2014 • 2015 ACR/ARHP Annual Meeting
Deficiency of IL-27 Exacerbate Sjögren’s Syndrome through Inhibiting Differentiation of Type 1 Regulatory T Cells
Genhong Yao¹, Bingyu Shi¹, Jingjing Qi¹, Ying Wang¹, Weiwei Chen¹, Xiaojun Tang¹, Dandan Wang², Xuebing Feng¹ and Lingyun Sun¹, ¹Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²Department of Rheumatology and immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: Sjögren's Syndrome (SS) is a systemic autoimmune disease characterized by chronic inflammation involving the exocrine glands, particularly the salivary and lacrimal glands. The pathogenesis…
Abstract Number: 2803 • 2015 ACR/ARHP Annual Meeting
Systemic Interferon Type I and Type II Signatures Present in Distinct Subsets of Primary Sjögren’s Syndrome: En Route Towards More Selective Targeting
Naomi I Maria¹, Cornelia G. van Helden-Meeuwsen¹, Eline C. Steenwijk¹, Arne S. IJpma², Zana Brkic¹, Paul L. van Daele^1,3, P. Martin van Hagen^1,3, Peter J. van der Spek², Hemmo A. Drexhage¹, Wan-Fai Ng⁴ and Marjan A. Versnel¹, ¹Immunology, Erasmus Medical Center, Rotterdam, Netherlands, ²Bioinformatics, Erasmus Medical Center, Rotterdam, Netherlands, ³Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands, ⁴Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease with a large heterogeneity in clinical phenotype. The IFN type I signature is present in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].